Serous Effusion Cytology in Sudanese Patients

ORIGINAL ARTICLE
Muaz Osman Fagere, Shawgi A. Elsiddig, Anass M. Abbas, Manar G. Shalabi, Asaad M.A. Babker

 
International Journal of Biomedicine. 2022;12(1):160-163.
DOI: 10.21103/Article12(1)_OA20
Originally published March 10, 2022

Abstract: 

The purpose of this study was to determine the etiology and cytological patterns of serous effusions among Sudanese patients.
 Methods and Results: This descriptive study was carried out in hospitals of Khartoum state in the period from February 2019 to June 2020.  One hundred and seventy-eight patients “clinically and/or radiological” diagnosed as having an accumulation of serous effusions were included in this study. Smears were prepared and stained according to the conventional pap staining procedure.
The majority of the study population (121[68%]) had malignant effusion (MEs), and the other group (57[32%]) - benign effusions (BEs). Among patients with MEs, breast cancer was the major etiology (75[62%]), followed by lung (23[19%]), GIT (12[9.9%]), and thyroid cancers (11[9.1%]), while among patients with BEs, parapneumonic conditions were the main factor (28[49.1%]), followed by tuberculosis (18[31.6%]) and pulmonary embolism (11[19.3%]). The majority of patients with MEs were pleural effusion (109[90.1%]), followed by peritoneal effusion (12[9.9%]), whereas no patients in this group had pericardial effusion. Pleural effusion (29[50.9%]) was also the major one among patients with BEs, followed by peritoneal (21[36.8%]) and pericardial effusions(7[3.9%]).
Conclusion: Malignant serous effusion is commonly seen among patients with malignant tumors; pleural effusions presented a large proportion, especially among females with breast cancer. Thoracentesis and cytological methods (i.e., conventional smear and cell block technique) should be the first line for the diagnosis of malignant pleural effusions, along with confirmatory adjunct techniques such as immunohistochemistry and immunocytochemistry.

Keywords: 
serous effusion • malignancy • cytology • malignant effusion • benign effusion
References: 
  1. Michailova KN, Usunoff KG. Serosal membranes (pleura, pericardium, peritoneum). Normal structure, development and experimental pathology. Adv Anat Embryol Cell Biol. 2006;183:i-vii, 1-144, back cover. PMID: 16570866.
  2. Davidson B. Malignant effusions: from diagnosis to biology. Diagn Cytopathol. 2004 Oct;31(4):246-54. doi: 10.1002/dc.20133.
  3. Baykus N, Özekinci S, Erdem ZB, Vurgun E, Yildiz FR. Comparison of Morphological Similarities and Differences between Liquid-Based Cytology and Conventional Techniques of Serous Effusion Cytology Specimens. Acta Cytol. 2021 Dec 30:1-6. doi: 10.1159/000521052.
  4. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest. 2000 Jan;117(1):79-86. doi: 10.1378/chest.117.1.79.
  5. Thomas R, Lee YC. Causes and management of common benign pleural effusions. Thorac Surg Clin. 2013 Feb;23(1):25-42, v-vi. doi: 10.1016/j.thorsurg.2012.10.004. 
  6. Light RW. Pleural effusions. Med Clin North Am. 2011 Nov;95(6):1055-70. doi: 10.1016/j.mcna.2011.08.005.
  7. Fagere MOM. Diagnostic utility of AgNORs staining of serous effusion among Sudanese patients. International Journal of Science and Technology. 201;5(1):36-42.‏
  8. Pinto D, Chandra A, Schmitt F. The International System for Reporting Serous Fluid Cytopathology: How to Incorporate Molecular Data in Cytopathology Reports. Journal of Molecular Pathology. 2021;2(2):66-76. doi: 10.3390/jmp2020007
  9. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol. 2005 Mar;32(3):151-5. doi: 10.1002/dc.20203. 
  10. Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindán J. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer. 2001 Feb 25;93(1):68-72. 
  11. Ahuja S, Malviya A. Categorisation of serous effusions using the International System for Reporting Serous Fluid Cytopathology and assessment of risk of malignancy with diagnostic accuracy. Cytopathology. 2021 Dec 15. doi: 10.1111/cyt.13089. 
  12. Elamin A, Ibrahim ME, Abuidris D, Mohamed KE, Mohammed SI. Part I: cancer in Sudan—burden, distribution, and trends breast, gynecological, and prostate cancers. Cancer Med. 2015 Mar;4(3):447-56. doi: 10.1002/cam4.378.
  13. Shalabi MG, Abbas AM, Mills J, Kheirelseid MA, Elderdery AY. The Prognostic Value of Estrogen Receptor β Isoform With Correlation of Estrogen Receptor α Among Sudanese Breast Cancer Patients. Breast Cancer (Auckl). 2021 Feb 25;15:1178223421998354. doi: 10.1177/1178223421998354. 
  14. M Abbas A, Shalabi MG, A Elsiddig S, Eltahir Z, M A Babker A, G Ahmed H. Evaluation of Angiogenesis by Using CD105 and CD34 in Sudanese Breast Cancer Patients. Pak J Biol Sci. 2021 Jan;24(11):1144-1151. doi: 10.3923/pjbs.2021.1144.1151.
  15. Aydogmus U, Ozdemir S, Cansever L, Sonmezoglu Y, Kocaturk CI, Bedirhan MA. Bedside talc pleurodesis for malignant pleural effusion: factors affecting success. Ann Surg Oncol. 2009 Mar;16(3):745-50. doi: 10.1245/s10434-008-0263-x. 
  16. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006 Feb;129(2):362-368. doi: 10.1378/chest.129.2.362. 
  17. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, Rodriguez Panadero F, Sahn SA. Management of malignant pleural effusions. Eur Respir J. 2001 Aug;18(2):402-19. doi: 10.1183/09031936.01.00225601. 
  18. Sahn SA. Malignant pleural effusions. Semin Respir Crit Care Med. 2001 Dec;22(6):607-16. doi: 10.1055/s-2001-18796.

Download Article
Received January 18, 2022.
Accepted February 4, 2022.
©2022 International Medical Research and Development Corporation.